调脂治疗在冠心病预防中的研究进展  

Recent Developments in Prevention of Coronary Heart Disease with Lipid Management

作　　者：耿婕[1] 陈树涛[1] 王林[2] 

机构地区：[1]天津市胸科医院CICU科,天津300051 [2]天津医科大学第二医院老干部保健科,天津300211

出　　处：《医学综述》2012年第4期596-599,共4页Medical Recapitulate

基　　金：天津市卫生局科技基金(2011KZ60)

摘　　要：在冠状动脉粥样硬化性心脏病(简称冠心病)一级和二级预防中调脂治疗可以降低心血管疾病的发病率和病死率。使用他汀类药物降低低密度脂蛋白的水平仍然是治疗的首要目标。对于二级预防的患者,即患有冠心病或冠心病等位症,推荐积极地降低低密度脂蛋白,尽管它的精确目标值仍在讨论中。对于冠心病的初级预防,即具有冠心病易患因素的患者降低低密度脂蛋白的水平仍然是必要的。在临床实验结果中证实,对于那些中危到高危的患者他汀类治疗获益较大,而低危的患者获益较小。Lipid management in primary and secondary prevention of atherosclerotic coronary heart disease（CHD for short）reduces cardiovascular morbidity and mortality.Lowering of low-density lipoprotein cholesterol levels with statins remains the primary goal of therapy.For secondary prevention patients,those with coronary heart disease or coronary heart disease risk equivalents,intensive low-density lipoprotein cholesterol lowering is recommended,although the precise target value is stillin discussion.For primary prevention,reduction in low-density lipoprotein cholesterol levels is based on patient risk for coronary heart disease.In clinical outcome trials to date,statins benefit those who are at moderate to high risk and appear to have less clinical benefit for those at low risk.

关 键 词：调脂治疗 预防 他汀类 

分 类 号：R541.4[医药卫生—心血管疾病]